- Home
- NPKI vs CRGX Comparison
NPKI vs CRGX Comparison
Compare NPKI & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- CRGX
- Stock Information
- Founded
- NPKI 1932
- CRGX 2021
- Country
- NPKI United States
- CRGX United States
- Employees
- NPKI N/A
- CRGX 170
- Industry
- NPKI Metal Fabrications
- CRGX
- Sector
- NPKI Industrials
- CRGX
- Exchange
- NPKI Nasdaq
- CRGX Nasdaq
- Market Cap
- NPKI 634.0M
- CRGX 621.4M
- IPO Year
- NPKI N/A
- CRGX 2023
- Fundamental
- Price
- NPKI $7.23
- CRGX $13.44
- Analyst Decision
- NPKI
- CRGX Strong Buy
- Analyst Count
- NPKI 0
- CRGX 6
- Target Price
- NPKI N/A
- CRGX $31.80
- AVG Volume (30 Days)
- NPKI 524.4K
- CRGX 298.6K
- Earning Date
- NPKI 02-19-2025
- CRGX 11-12-2024
- Dividend Yield
- NPKI N/A
- CRGX N/A
- EPS Growth
- NPKI N/A
- CRGX N/A
- EPS
- NPKI N/A
- CRGX N/A
- Revenue
- NPKI $748,372,000.00
- CRGX N/A
- Revenue This Year
- NPKI N/A
- CRGX N/A
- Revenue Next Year
- NPKI N/A
- CRGX N/A
- P/E Ratio
- NPKI $18.70
- CRGX N/A
- Revenue Growth
- NPKI 93.70
- CRGX N/A
- 52 Week Low
- NPKI $5.61
- CRGX $12.17
- 52 Week High
- NPKI $8.65
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- CRGX 40.40
- Support Level
- NPKI N/A
- CRGX $13.65
- Resistance Level
- NPKI N/A
- CRGX $15.75
- Average True Range (ATR)
- NPKI 0.00
- CRGX 1.20
- MACD
- NPKI 0.00
- CRGX 0.10
- Stochastic Oscillator
- NPKI 0.00
- CRGX 37.57
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.